Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 712704 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Search Results

Your Search for 'Macular Degeneration: Treatment. (Article)' returned 5 results - Page 1 of 1

  Sort by   
  Sorted by Rank Top-Bottom

2nd World Congress on Controversies in Ophthalmology 2011: Post-Conference Review and Analysis  
GlobalData, March 2011, Pages: 15
Induced Optic Neuropathy 3 Abbreviations 4 Disclaimer 1.1 List of Tables Table 1: Treatment Pattern of VEGF Suppression in AMD 1.2 List of Figures Figure 1: Macular Degeneration Therapeutics


Immunology, Inflammation and Diseases of the Eye  
Elsevier Science and Technology, March 2011, Pages: 448
Immunobiology of uveal melanoma Immunobiology of age-related macular degeneration Pathogenesis and Immunology of Bacterial endophthalmitis II. Angiogenesis in the Eye and Its Dysfunction in the Retina, Cornea


Pricing and Reimbursement: Innovative Risk-Sharing Strategies  
Datamonitor, July 2009, Pages: 53
for wet age-related macular degeneration Merck & Co. incentivizes Januvia uptake providing bigger discounts on positive clinical outcomes for diabetes patients in the US Strong head-to-head clinical data


Massachusetts General Hospital - Product Pipeline Analysis  
GlobalData, Oct 2011, Pages: 21
Clues To Development Of Macular Degeneration Jul 10, 2011: MGH Researchers Develop One-Micrometer-Resolution Version Of Intravascular Imaging Technology Jul 01, 2011: Massachusetts General Hospital


Drug Repositioning Strategies - Serendipity by design  
Datamonitor, May 2008, Pages: 93
: Avastin versus Lucentis for age-related macular degeneration 67 Figure 26: Issues impacting drug repositioning in the future 70 Drug Repositioning Strategies - Serendipity by design


Results:  First -   Prev -   1 -   Next -   Last


For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-800-526-8630 (US/Canada Toll Free)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds